Archive for July, 2006

StockGuru Blog: The Launch of the First Two City Bus Lines in Yaounde, Cameroon, is Scheduled for early September

Monday, July 31st, 2006
The Launch of the First Two City Bus Lines in Yaounde, Cameroon, is Scheduled for early September

Transnational Automotive Group (OTCBB: TAMG)

One step at a time best describes “Le Bus”, the name of the bus line that Transnational Automotive Group, Inc. is establishing in Cameroon, with support from the Cameroon government. Once the twenty-eight buses are unloaded at the port city of Doaula, Cameroon, the buses will be escorted for the seven mile drive to the protected safety of the Civil Military Engineer Base. The Minister of Defense of Cameroon has offered Brigadier General Saly and the base for logisitics and training in Douala for forty of the newly hired drivers, who will train at the base before driving the buses under guard inland to Yaounde.

The Company’s first 28 buses, under its Cameroon public transport contract, arrived at the port of Douala on 22 July, and were unloaded from the cargo ship, BBC Germany. The buses, seventeen urban buses and eleven rural buses, arrived in very good condition after their ocean voyage. Only one bus required minor repair. Otherwise, the buses were inspected by Company technicians, cleaned, and serviced before moving to port storage pending customs formalities.

Joseph W. Parker, Board Chairman of the Transnational Automotive Group, Inc, underscored the fact that transportation companies do not spring up like mushrooms overnight. “There is a lot of technical planning for maintenance and spare parts, recruiting of people including drivers and security men, etc.” Earlier Mr. Parker had encouraged the 2,500 people who had initially applied for position with Le Bus to continue to check for new openings.

“Le Bus” Managing Director Bokwe Mofor, discussed the long awaited arrival of the hope of public transportation to the county as a milestone in social advancement. “The arrival of the buses is an important day in the history of Cameroon. The people of this country have been without reliable urban and rural transport for almost fifteen years. We will now be able to begin providing safe, modern, comfortable transport for office workers, school children, and every Cameroonian who has longed for this occasion. The arrival of these buses is literally a dream-come-true for all Cameroon and portends better days to come.”

Sources:
Market Wire AND
Cameroon Tribune/All Africa Global Media via COMTEX

View the StockGuru Profile for Transnational Automotive Group:

http://www.stockguru.com/profiles/tamg/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $46,000 by a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru Blog: The Immune Response Corporation Sees Valuation Pressure Relieved with Warrant Expiration Imminent

Monday, July 31st, 2006

IMNR – The Immune Response Corporation should experience a relief of recent valuation depression this week.

The overhang of 600MM warrants @ $0.02 per share is virtually gone. The warrants expire on 8/7/06, and with 3-day settlement warrant-holders are no longer able to sell and exercise their warrants. This should relieve enormous pressure from the stock. The financing has been absorbed. The next set of warrants do not become exercisable until October 16 through November 30.

IMNR stock closed at $0.24 per share, ten times where it is currently trading, on March 7, 2006, the day the financing was announced. Given the market cap, the currently depressed valuation could be largely attributed to the pressure from the financing. It is anticipated that the warrant expiration should relieve a great deal of the valuation pressure, potentially creating a very strong point of entry for investors today, at current levels.

ABOUT THE IMMUNE RESPONSE CORPORATION The Immune Response Corporation (OTCBB: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. Their lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of multiple sclerosis (MS) and IR103 for the treatment of Human Immunodeficiency Virus (HIV). Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. NeuroVax™, which is based IMNR’s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong disease specific cell mediated immunity in nearly all patients treated by enhancing levels of FOXP3+ T Regulatory (Treg) cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease.

In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.

Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.

Disclosure: Pentony Enterprises LLC was compensated $17,500 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: Publisher@Stockguru.com.

For further information contact:
ROI Group Associates
39 Broadway; NY, NY 10006
212.495.0744
abrown@roiny.com

Source:

IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080

StockGuru Blog: Tasco Holdings International Focuses on Adult Stem Cell Storage and Research

Monday, July 31st, 2006

This Field Is in the Nascent Stage

Tasco Holdings International (OTCBB: THII)

Bio-Matrix’s Chairman and CEO David Koos Discusses Advantages of THII

Bio-Matrix Scientific Group, Inc., (BMXP) a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced that its chairman and CEO, David R. Koos, was the key speaker on Agoracom’s CEO Interview where he summarized the sale of BMXP’s wholly owned subsidiary and operating entity, Bio-Matrix Scientific Group, Inc., (BMSG Nevada) to Tasco Holdings International, Inc., (THII).

Koos also stated noted that the OTC Bulletin Board is viewed as offering the potential for greater access to institutional investors. “On the Bulletin Board, the company will be more transparent to potential institutional investors. We believe that institutional investors are important to the company, as they may be able to facilitate a more rapid implementation of the business model and potential future revenues streams.”

Koos also updated the status of BMSG Nevada’s new Stem Cell Cryogenic facility, “Currently, the processing laboratory is under construction and should, based on our current estimates, be completed by the end of August 2006. Once completed, the facility will undergo extensive testing. The Class 10,000 clean room labs should be completed by the end of August 2006. The company currently anticipates that if third party commitments the company has received remain on schedule, the company believes it will be ready for specimens in the first part of the 4th quarter of 2006.”

Source: Obesity, Fitness & Wellness Week and News RX.com
Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517

About Tasco Holdings Inc.

Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.

Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.

Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

StockGuru Welcomes Tasco Holdings International (OTCBB: THII)

Monday, July 31st, 2006

StockGuru Welcomes

Tasco Holdings International Inc.
(OTCBB: THII)

View the StockGuru Profile for Tasco Holdings International Inc. (OTCBB: THII):

http://www.stockguru.com/profiles/thii/

Tasco Holdings International Inc.

Tasco Holdings International Inc. (OTCBB: THII) is a development stage company that recently acquired Bio-Matrix Scientific Group, Inc. The Company is engaged in the cryogenic storage of stem cells and the development of medical devices used in live tissue transfer and stem cell research. Additionally, the Company has developed 192 disposable instruments for use in plastic surgery, tissue management and stem cell research. These instruments have been designed to harvest adult stem cells from adipose tissue. The company plans to commercialize these instruments to plastic surgeons and patients to help store stem cells derived from their adipose tissue (extracted primarily during the liposuction process).

State-of-Art Facility

Tasco Holdings/Bio-Matrix is currently in the process of constructing a 15,000 square foot state-of the-art facility at San Diego for the processing and cryo-storage of adult stem cells. In addition to stem cell bank and research laboratory functions, this facility will also be engaged in the development of stem cells and medical devices that can be used in tissue management for human and veterinary applications. The building will house the company’s secure cryogenic adult stem cell bank, aseptic cellular/tissue processing room, hematology, microbiology and flow cytometry laboratories. Additionally, this facility will have three separate research laboratories, a tissue management/stem cell instrumentation division, and a marketing and corporate office. The building, situated in the heart of San Diego, is expected to be ready by the end of September.

Stem Cell Activities

Tasco/Bio-Matrix is focused on the development of stem cell banks for the cryo-preservation of adult stem cells. People can save their stem cells to help fight diseases like Diabetes, Osteoporosis, Parkison’s and other heart-related problems, which may arise in the future. Stem cells, which have been frozen in suspended nitrogen, are no longer subject to the aging process. As a result, these cells possess the same functions and activity which they possessed on the day they were collected. What makes the company stand out in the marketplace is the fact that the company is expected to be the first one that can store stem cells harvested from the adipose tissue of human beings. There are several companies that provide the facility to store cord blood stem cells. Given the increasing number of liposuctions taking place in the U.S., there should be significant demand for the processing and storage of stem cells from fat tissue.

Marketing Initiatives

The company plans to enter into agreements with end-use manufacturers, marketing and distribution channels in exchange for licensing fees, royalties and other compensation. The company has already entered into an agreement with Cord Blood America, Inc., for the marketing of its adipose stem cell banking services. As per the terms of the agreement, Cord Blood Bank America will be entitled to a 40% share of the fees collected. Management is primarily planning to market its stem cell banking services to plastic surgeons, hospitals and medical schools. The company plans to market its services to these targeted markets through extensive advertising and promotional efforts.

Stem Cell Instrumentation

Tasco/Bio-Matrix has developed approximately 192 disposable instruments for use in plastic surgery and stem cell research. These instruments have been so designed that they can be used to extract stem cells from adipose tissue. Management plans to market and sell these instruments to plastic surgeons and patients to help store stem cells for medical treatments. The American Society of Plastic Surgeons has recently reported that liposuction has become the most common procedure amongst cosmetic surgery procedures. Since these surgical instrument kits have been designed to provide direct assistance in the liposuction process, the company could raise significant revenues from their sale. Additionally, the Company has developed veterinary stem cell instrumentation for stem cell therapy. These instruments are currently in the beta testing stage and are expected to be of use in both large sized as well as small sized animals including thoroughbred horses, elephants, dogs and cats. Tasco/Bio-Matrix appears committed to improving the quality of veterinary stem cell medicine by further developing solutions to meet the current needs of veterinary biotechnology.

Patent Applications

Realizing the need to maintain intellectual proprietary, Tasco/Bio-Matrix has already applied for six provisional patents, one utility patent and one international patent application (as of February 2006) for the different instruments developed by it. These instruments would be used for harvesting stem cells, transferring tissue and for other extraction procedures. The company has appointed a patent attorney in the recent past to assist in the filing of these patents.

Proprietary Polymer Coating

Recently in February 2006, Bio-Matrix Scientific Group announced that it is developing a proprietary polymer coating for its stem cell and tissue management instruments, which would help to reduce friction in procedures and lead to greater predictability. At the time of the removal of tissue or stem cells, it is of utmost importance to minimize exposure to rough surfaces. The company believes that this polymer coating will help to minimize damage to cells. Once the development of this coating is complete, the company plans to retain exclusivity through a patent.
Stem Cell Industry Analysis

Stem cells are simply cells that have the ability to replicate themselves during the life of an organism, and give rise to mature cells that have the shapes and functional abilities of specialized cells (like heart cells or nerve cells). Human embryonic and adult stem cells have their own sets of advantages and disadvantages in cell-based regenerative therapies. The former cell type has the ability to become all cell types of the body, whereas adult stem cells can only differentiate into different cell types of their tissue of origin. However, adult stem cells (which have the ability to transform into all other cell types and revert back to being stem cells with greater reproductive capacity) have been successfully used in various surgeries, especially cardiac infarction. They have shown great possibilities in the treatment of diseases and conditions like diabetes, osteoporosis, Parkinson’s, Alzheimer’s, spinal cord injuries and burns. Recent research reports show that the adult stem cell is versatile and capable of transforming into various other cell types, like blood to brain or liver to blood, enhancing the chances of survival in life threatening diseases.

Currently, approximately $15 billion is spent annually to treat bone, cartilage and other connective structure injuries using allogra?, autologous gra?s and synthetic materials. There is also a shortage of replacement organs that are critical for life saving purposes. These can be resolved by stem cell technology, which can help grow new organs from a few cells and encourage an organ or tissue to repair itself.

Adult stem cells can be harvested from umbilical cord blood, adipose tissue or bone marrow. Stem cells from fat tissue are known for their quality and quantity, and can be derived through liposuction, which is a less invasive procedure as compared to that required to take stem cells from other tissues. Adipose tissue contains stem cells that can be used to regenerate bone, cartilage, heart muscle and nerve tissues, which makes the treatment of heart diseases much easier. The trend for liposuction has grown in the recent past, and reports show that the U.S. demand for cosmetic surgery products will grow 11.2% yearly through 2007, driven by new products, favorable cultural and demographic trends and improved technology. Non-surgical products like injections and dermabrasions are likely to lead the market. In 2004, American men and women between 35 and 40 had 5.3 million surgical and non-surgical cosmetic surgeries, while those between 51 and 64 had around 2.9 million. This trend is expected to grow further, providing an impetus to harvesting stem cells derived from adipose tissue. Reproductive cells and blood cells have been successfully stored at ultra low temperatures to suspend cellular metabolism for more than 15 years, and then unfrozen and transplanted into the patient’s body when required.

Stem cell banking facilities have been available in the U.S. for fitteen years and there are currently 23 cord blood banks operating in the country. Three companies — Cryo-Cell International, Inc., Cord Blood Registry and Viacell, Inc. — collectively own 80% of the market share. However, compliance with the Food and Drug Administrations’ operation requirements provide a major entry barrier into the stem cell banking industry, as there are significant costs associated with compliance.

Today’s stem cell therapies depend on cells donated by other people, thereby raising the chances of the patient’s immune system rejecting the donor cell. Current research may make it possible for people to use their own stem cells to regenerate tissue. Scientists believe that they will soon be able to manipulate stem cells taken from adults to create new tissue in the lab and re-transplant the same in the patient’s body, where it can work to restore an impaired function. Apart from that, therapeutic cloning may also help in the creation of embryonic stem cells, genetically similar to the patient. Another possibility is to develop a drug that would direct a stem cell to restore the lost function in a patient’s body. This would also do away with the invasive surgical procedures required to harvest and transplant stem cells. Some examples of treatments include replacing the dopamine-producing cells in the brains of people with Parkinson’s, developing insulin producing cells for Type I Diabetes, and repairing damaged heart muscles atter a heart attack with cardiac muscle cells.

Management
David Koos Chief Executive Officer and Director

Davis Koos, the current CEO, officer, and Director of Tasco holds an extensive background in investment banking, venture capital, and investor relations. He also holds the position of a Chairman, CEO and acting CFO of Freezer, Inc. and Chief Executive Officer of Bio-Matrix Scientific Group, Inc. Dr. Koos has worked with major Wall Street Investment Banks including Sutro & Co., Everen Securities, and Dean Witter. Dr. Koos is the founder and a director at Venture Bridge, Inc. Additionally, he has been the Co-Founder, Director, President and Managing Director of Cell Source Research Inc. Dr. Koos holds a Series 7 and a Series 24 securities license and a Ph.D. degree in Economic Sociology and a DBA in Corporate Finance, both from Atlantic International University. Dr. Koos has also completed his masters in Economic Sociology from the University of California and is currently pursuing a Doctor of Business Administration degree in financial Management from Northcentral University.
Brian Pockett Chief Operating Officer, President, and Director

Mr. Brian Pockett, the current COO, President, and Director of Tasco holds over 29 years of experience in operations, marketing, sales and financial & grant development at various Corporate. He is also the Managing Director and Chief Operating Officer of Bio-Matrix Scientific Group, Inc. as well as the Managing Director and Chief Operating Officer of Freezer, Inc. Mr. Pockett founded PD&C (a private consulting firm) and served as a consultant to some of the largest companies in North America including Disney, SONY, Nintendo, Acclaim Entertainment, and UFO. His work has included global distribution, product development, commercialization, investment and intellectual properties. Mr. Pockett holds a B.A. degree from Azusa Pacific University and a Theology Degree from Crestmont Seminary.

View the StockGuru Profile for Tasco Holdings International Inc. (OTCBB: THII):

http://www.stockguru.com/profiles/thii/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4268. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $10,000 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru News: 110 Media Group (ONTN) Is Now Web2 Corp. (WBTO) – New Name and Symbol Signals Web2’s Mission to Be a Leader Among the Next Generation Web 2.0 Companies

Monday, July 31st, 2006
110 Media Group (ONTN) Is Now Web2 Corp. (WBTO)

New Name and Symbol Signals Web2’s Mission to Be a Leader Among the Next Generation Web 2.0 Companies

ORLANDO, Fla., July 31 /PRNewswire-FirstCall/ — 110 Media Group, Inc. (OTC Bulletin Board: ONTN – News) announced today that it has completed its name change to Web2 Corp. and now trades on the Nasdaq OTC:BB Electronic Quotation Service under the stock symbol “WBTO.”

Under the new identity, Web2 has re-oriented its mission and plans to begin release of an array of new Internet products, beginning with the launch of the Chamber of E-Commerce for the business community. The Chamber of E-Commerce provides a resource center for small businesses that has not previously existed. It offers a variety of reference materials, promotional directories, a community place for virtual business owners to gather, and a selection of services and products to encourage and simplify e-business. “Our goal is to arm the vast numbers of non-technical business owners with e-commerce products that let them stay focused on their business, not on learning arcane details of the Web,” says William Mobley, Chairman of Web2 Corp. “We are the non-techie do-it-yourself solution that is perfect for eBay sellers who want their own website, or small business operators who have avoided the Internet. We target non-consumers by making the process easy, fun, fast and very affordable.”

Aiming to harness the power of new technologies to simplify productive use of the Internet, Web2 has numerous products in the queue for launch, including a new form of search engine, an adaptation of social network technologies for business use, and an array of e-commerce solutions that integrate the most- used features of established competitive products into one easy-to-use suite under the Chamber of E-Commerce. Web2 thrives on identifying areas of user frustration. It then sets about creating products that simplify the process and eliminate the sources of friction. In doing so, the company levers the latest technology and combines it with a dose of common sense in designing an intuitive product that integrates the 20% of features that 80% of users desire. The goal is to leapfrog incumbent competitors and profit through the sale of products that people want and will use daily.

Product rollout is expected to begin on August 1st with the release of the company’s e-commerce offers. Additional rollouts are expected in August and September in time for small businesses to utilize them in the fourth quarter.

ABOUT WEB2 CORP.

Web2 Corp. (OTC Bulletin Board: WBTO – News) products and services address a significant market gap by providing non-technical business operators of small to medium-sized businesses with all the necessary services needed to migrate their cottage industries to the Internet or to start a new Internet business. Web2 Corp’s Chamber of E-Commerce packages provide all the necessary components for a successful online business in just one hour. The Company’s integrated friendly, helpful, non-threatening bundle can be easily accessed and managed by low-tech business operators. The company profitably provides all elements basic to any business endeavor in a cost-effective package offered for $19.95 per month with no start-up fees. Clients simply need to add their information and products or services to be in business in as little as an hour without knowing a thing about HTML, Flash, Secure Socket Layers, FTP, or any other technical aspect of creating and running a website.

The company’s numerous products are vertically integrated and primed to become the easiest and most innovative Internet utilities since Yahoo! or Google, coupled with the viral rapid marketing growth of such first-to-market leaders as MySpace, MSN Hotmail, ICQ, Blue Mountain Arts and Napster.

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact included in this release, including without limitation statements regarding potential future plans and objectives of the Corporation, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Gross turnover could be substantially less in the future due to changes in the law, general economic conditions, or unexpected failure of equipment servicing the accounts. In addition, technical complications which may arise could prevent the prompt implementation of the plans outlined above. Additional Safe Harbor Act Disclaimer Notice is available on the web site at http://www.web2corp.com..

Source: Web2 Corp.

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC is expected to be compensated up to $16,000 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru News: Mobile Ready Entertainment Corporation (OTC:MBRN) Issues Letter of Intent to Valuetronix – MBRN Seeks to Acquire Small Business Tools With Mobile Capability

Monday, July 31st, 2006
Mobile Ready Entertainment Corporation (OTC:MBRN)

Mobile Ready Entertainment Corp. Issues Letter of Intent to Valuetronix

MBRN Seeks to Acquire Small Business Tools With Mobile Capability

STROUDSBURG, PA–Jul 31, 2006 — Mobile Ready Entertainment Corp. (OTC: MBRN) announced on Monday that it had submitted a Letter of Intent to acquire Valuetronix and their vServer technology and MicroOffice business platform.

“We are looking to increase our technology holdings and offerings and Valuetronix has some very compelling tools for our small and mid-sized business customers,” Josh Eikov, CEO of MBRN said.

The vServer is marketed towards the small business owner and separates itself from other servers by providing license-free highly integrated multi-functional capabilities. In other words, a vServer is an “all-in-one” server that can handle the most demanding of network services and application delivery that breaks the bonds of having to pay licensing per user. When installed in a small business, it is all you will need. A vServer provides network services like corporate mail and file sharing to enterprise grade web-based applications like groupware, customer relationship management, accounting, issue tracking and more. There is also a mobile interface that allows access and control over data and essential services such as email and groupware.

“Our portfolio is growing within the business segments we are targeting around the mobile theme. The addition of a great B2B tool such as the Valuetronix product is just more of MBRN’s commitment to serving the small business needs of America,” said Mary Hermant, MBRN General Manager.

For information about Valuetronix, Inc. please visit www.valuetronix.com

Forward-Looking Statement

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. The statements contained or incorporated by reference in this website that are not historical facts (including without limitation statements to the effect that Mobile Ready Entertainment Corp. (the “Company” or “Mobile Ready”) or its management “believes,” “expects,” “anticipates,” “plans,” “intends,” “foresees,” or other similar expressions) are forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company.

There can be no assurance that future developments affecting the Company will be those anticipated by the Company. All comments concerning the Company’s expectations for future revenue and operating results are based on the Company’s forecasts for existing operations and do not include the potential impact of any future acquisitions. These forward-looking statements involve significant risks and uncertainties (some of which are beyond the Company’s control) and assumptions.

Contact:

Mobile Ready Entertainment Corporation
Joshua Eikov
570-269-8303
josh@mymobilereadyec.com

View the StockGuru Profile for Mobile Ready Entertainment Corporation (OTC: MBRN):

http://www.stockguru.com/profiles/mbrn/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $15,000 by a non-controlling third party for profile coverage. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru Blog: Bio-Matrix’s Chairman and CEO David Koos Discuss Advantages of THII; Tasco Holdings International Focuses on Adult Stem Cell Storage and Research

Monday, July 31st, 2006
Tasco Holdings International (OTCBB: THII)

Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

Bio-Matrix Scientific Group, Inc., (BMXP) a biotechnology company focused on stem cell cryogenics and disposable stem cell/tissue transfer instruments, announced that its chairman and CEO, David R. Koos, was the key speaker on Agoracom’s CEO Interview where he summarized the sale of BMXP’s wholly owned subsidiary and operating entity, Bio-Matrix Scientific Group, Inc., (BMSG Nevada) to Tasco Holdings International, Inc., (THII).

Koos also stated noted that the OTC Bulletin Board is viewed as offering the potential for greater access to institutional investors. “On the Bulletin Board, the company will be more transparent to potential institutional investors. We believe that institutional investors are important to the company, as they may be able to facilitate a more rapid implementation of the business model and potential future revenues streams.”

Koos also updated the status of BMSG Nevada’s new Stem Cell Cryogenic facility, “Currently, the processing laboratory is under construction and should, based on our current estimates, be completed by the end of August 2006. Once completed, the facility will undergo extensive testing. The Class 10,000 clean room labs should be completed by the end of August 2006. The company currently anticipates that if third party commitments the company has received remain on schedule, the company believes it will be ready for specimens in the first part of the 4th quarter of 2006.”

Source: Obesity, Fitness & Wellness Week and News RX.com

Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517

About Tasco Holdings Inc.

Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.

Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.

Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

StockGuru News: Elgrande International and Cavico Corporation

Monday, July 31st, 2006

Elgrande International, Inc. (OTCBB: EGDI)

Elgrande International Signs Agreement With A.G. AUCTION PARTNERS to Begin eBay Distribution

VANCOUVER, BC–(MARKET WIRE)–Jul 31, 2006 — Elgrande International (OTC BB:EGDI.OB – News) announced today they have signed an exclusive agreement with A.G. AUCTION PARTNERS to begin distribution of their award-winning home décor products on eBay.

Read full release here:

http://stockguru.com/profiles/egdi/news.php

Cavico Corporation (OTC: CVCP)

Cavico Corporation to Begin Tunnel Works Excavation for USD $24 Million Nam Chien Hydropower Company Project

LOS ANGELES, CA and HANOI, VIETNAM–(MARKET WIRE)–Jul 31, 2006 — Cavico Corporation (Other OTC:CVCP.PK – News), a Vietnamese company working in the fields of infrastructure development, including the construction of hydropower facilities, dams, bridges, roads, mines and urban buildings throughout Vietnam and the Pacific Rim, has completed negotiations and signed a contract with Nam Chien Hydropower Company to begin construction on its tunnel works project. The value of this contract to Cavico is approximately 384 billion VND ($24 million USD equivalent).

Read full release here:

http://stockguru.com/profiles/cvcp/news.php

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. EGDI Disclosure: Pentony Enterprises LLC was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this. CVCP Disclosure: Pentony Enterprises LLC was compensated 6,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

July 31st CEOcast Weekly Newsletter

Sunday, July 30th, 2006

07/30/2006
VOLUME 249
Companies featured in the current edition of the newsletter: ADSX, ASPN, CYTR, GNBT, GSHF, HMWM, HSOA, HYTM, IMMG, ISON, IVOI, NTRN, NTST, NVLT, PTCH, SCLL, UDTT, USAT, ZIOP

The stock market was kind to bulls this week as optimism about profit growth and possible easing of Fed tightening led the major indices higher. Also helping investors was the rally in the Treasury market that pushed the yield on the 10-year Treasury note below the psychologically significant 5%. The Dow gained 351 points for the week, increasing yearly gains to 4.7%. The Nasdaq recovered from last week’s decline and rose 74 points, reducing year-to-date losses to 5%.  The S&P rose 38 points, raising annual gains to 2.4%. The Russell ended the week 28 points higher resulting in a 4% annual gain.

The Dow posted its largest weekly advance in more than a year and the S&P had its best weekly point gain in over three years. A very busy earnings calendar from the week gave investors something to smile about as strong earnings reports from Merck (NYSE: MRK), General Motors (NYSE: GM) and ConocoPhillips (NYSE: COP) helped offset a disappointing report from Amazon.com (NASDAQ: AMZN). Investors were enthusiastic about overall Q2 results which are on track to equal 13.6% as a result of already reported results and estimates. This trend should continue as analysts are estimating 15 percent profit growth in the third quarter and 14.2 percent profit growth in the fourth quarter for S&P companies. A handful of economic reports also helped drive stocks upward as sales of new homes in June fell 3.0% from May and 11% from a year ago lending support of taming inflation.  Additionally, a government report issued by the Commerce Department indicated that growth in the U.S. economy was slower than anticipated in the second quarter, reducing the likelihood that the Fed will increase interest rates at its August meeting. Further fueling momentum was the further decline of oil prices which ended at $73.24 per barrel, down 1.6% for the week.

What should investors look for in the coming quarter? There are still many companies scheduled to report earnings, including Humana (NYSE: HUM) on Monday morning. Tuesday, before the open, International Paper (NYSE: IP) and Marathon Oil (NYSE: MRO) announce numbers followed by Computer Sciences (NYSE: CSC) after the close. Prior to the bell on Wednesday Devon Energy (NYSE: DVN) releases earnings along with Proctor & Gamble (NYSE: PG). Cardinal Health (NYSE: CAH) reports figures before the bell on Thursday. Investors should also get a closer look at the impact of higher energy prices on consumers as a number of retailers report sales releases with automotive giants General Motors (NYSE: GM) and Ford Motor Company (NYSE: F) announcing on Tuesday and Hot Topic (NASDAQ: HOTT), Aeropostale (NYSE: ARO), American Eagle (NASDAQ: AEOS), Men’s Wearhouse (NYSE: MW) and Starbucks (NASDAQ: SBUX) reporting results on Wednesday. Credit Suisse hosts its three-day Electrical Equipment & Multi-Industry Conference beginning Wednesday in Southampton. Robert W. Baird & Co. hosts its one day Oncology Conference in New York where ZIOPHARM Oncology, Inc. (OTCBB: ZIOP) will be presenting on Wednesday as well.

The economic calendar will be busy as well highlighted by Friday’s Employment Report, where expectations are that 140,000 new jobs were created in July above the 121,000 in June. The Unemployment Rate is expected to remain at 4.6%. Hourly Earnings and Average Workweek numbers will also be announced Friday morning, with wage increases scrutinized. Beginning the week will be the release of the July Chicago PMI Monday after the opening bell. Tuesday morning, June Personal Income and Spending numbers will be reported followed by June Construction Spending and the July ISM Index shortly after the bell. Weekly Crude Inventories will be announced on Wednesday after the opening bell. Thursday morning, Weekly Jobless Claims will be reported followed by June Factory Orders and July ISM Services. Much attention will be placed on various Fed speakers throughout the week with St. Louis Fed president Poole speaking at the southern Legislative Conference on Monday and San Francisco Fed president Yellen also speaking on the economy in San Francisco that same day. On Friday Minneapolis Fed president Stern will talk on banking issues in Minnesota.

Hythiam, Inc. (NASDAQ: HYTM), a healthcare services management company that licenses the PROMETA™ physiological protocols designed to treat substance dependence, has signed its first PROMETA licensing agreement with Canterbury Institute that will create an outpatient center to treat those suffering from addiction. Hythiam will receive a 10% equity ownership in Canterbury in addition to fees for services and technology licensing. Additional PROMETA centers under this agreement will be opened in Northern New Jersey and in Southern Florida where Canterbury will place $2 million is escrow for such openings. Further strengthening brand recognition, approximately $250,000 will be allocated towards annual marketing for each location. This strategy is expected to grow Hythiam’s top-line as early indications of this licensing model from a demonstration site are impressive which show profitability and high volume. One of the key benefits to this model is that it helps those who cannot afford to be away from work and family for weeks or months at a time by treating them on an out-patient basis. Hythiam is looking to build a strong network of licensees to complement each of Canterbury Institute’s PROMETA Centers. It plans to open another company managed PROMETA Center in San Francisco. Providing further validation of the protocols, the City Court of Gary, Indiana presented data on offenders treated with Hythiam’s PROMETA Protocols at the American Probation and Parole Association’s 31st Annual Training Institute. This presentation highlighted the durability of positive outcomes six months after the initiation of treatment. Such statistics, which showed 95% of aggregate urine samples screening negative for use 6 months after treatment and 80% of PROMETA participants maintaining drug court compliance and remain drug free, overwhelmingly  surpassed the Court’s historical success rates. Additionally, the company appointed leading addiction treatment executive Chris Hassan as Senior Executive Vice President and will oversee the company’s licensing and marketing efforts. Most recently, Hassan was a founding member and vice president of sales of Reckitt Benckiser pharmaceuticals, where he was responsible for the initial commercial planning and launch of the highly successful new innovative treatment for opiate addiction – Suboxone™ (buprenorphine). Reckitt Benckiser is a $25 billion global enterprise. The stock ended the week at $4.99, up 2 cents.

The battle between the longs and shorts in Home Solutions of America (NASDAQ: HSOA), a provider of a provider of recovery, restoration and rebuilding/remodeling services, could heighten in the coming weeks as the company is expected to report second quarter results for the period ended June 30, 2006 during the week of August 7th. Shares have slipped to mid-February levels, in part due to a surge in short interest (nearly 40% of the float is short) and as a result of controversy surrounding insider sales, and an agreement with American Renaissance Homes, a recently formed provider of affordable housing. Ironically, while concerns surrounding that contract have contributed to the significant decline in the company’s shares (down more than 50% since late May), the opportunity could be even more significant than even the company anticipated. On Saturday, according to The New Orleans Times Picayune, the area’s leading newspaper, more than 1,000 people turned out for a St. Bernard Parish Modular Home Expo coordinated by members of the St. Bernard Parish Government suggesting strong interest in modular homes. Analysts expect the company to report Q2 revenue of $25 million and EPS of $0.07. If the company were to significantly exceed those estimates, it could help trigger a turn-around in beaten down shares of the company’s stock. Note that August brings the one-year anniversary of hurricanes Rita, Wilma and Katrina. Shares ended the week at $5.56, down 97 cents.

Netsmart Technologies, Inc. (NASDAQ: NTST), a leading provider of enterprise-wide software for health and human services organizations, along with its partner Saber Corporation will deliver an enterprise health system for the State of North Carolina Department of Health and Human Services (DHHS). The new Saber/Netsmart solution is expected to standardize and unify all health department clinical and financial transactions by providing an enterprise database and advanced data management and reporting capabilities. At the core of the Web-based solution is Netsmart’s Avatar software, a full-function, off-the-shelf software package designed to automate clinical, financial and management functions for community mental health, public health, and substance abuse providers and payers. Saber’s role will be to manage all aspects of this large-scale project and to integrate the customized Netsmart system among the state’s public health departments. The initial phase of the contract with North Carolina DHHS will replace several of the state’s aging public health information systems with a statewide solution serving all public health entities. It is valued in the amount of approximately $19.8 million over a 19-month period, and will be followed by 42 months of maintenance and support valued at approximately $4.7 million. Pursuant to the agreement, Netsmart will receive an estimated $10.5 million over the contract period for products and services provided by Netsmart. Shares were down 9 cents last week, closing at $12.80.

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical company focused on developing products primarily in the area of small molecules and ribonucleic acid interference (RNAi), achieved a significant milestone in the clinical development of  arimoclomol after the final patients in its Phase IIa received final dosing and follow-up. Such progress moves the company one step closer to commercialization as the company can now begin the process of data analysis. Such data analysis of this Phase IIa trial is expected to be completed in the upcoming months where final results will be released early in the fourth quarter of this year. In March 2006, arimoclomol was cited as one of the “100 Great Investigational Drugs in Development” by the pharmaceutical industry magazine R&D Directions in its fifth annual report. The stock gained 3 cents last week, closing at $1.19.

Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, expanded its patent coverage for its oral insulin product in a key commercial market and was awarded its first Japanese patents and a new United States patent. The Japanese patents each contain claims relating to an improved delivery system for the administration of large-molecule pharmaceuticals, which may be administered by means of an aerosol into the mouth, for buccal or pulmonary application. The United States patent contains claims relating to an improved delivery system for the administration of large-molecule pharmaceuticals which may be administered through the oral and nasal membranes. Generex has an impressive intellectual property portfolio and currently holds an aggregate of 76 patents worldwide (19 of which are United States patents) and has an aggregate of 51 patent applications pending in various jurisdictions. The stock ended the week at $1.42, up 11 cents.

Earnings Preview: Applied Digital (NASDAQ: ADSX), a leading provider of identification and security technology, is scheduled to report second quarter results for the period ended June 30, 2006 on Thursday before the market opens. Investors will better be able to assess the prospects for an IPO of VeriChip Corporation when the company announces sales of the unit that day. The company’s publicly held  majority-owned by subsidiary Digital Angel Corporation  will also announce results at the same time. Since its Q1 earnings releases, shares of ADSX have declined 42%, perhaps related to the delay in VeriChip going public. Last week, VeriChip Corporation reported a significant milestone for its VeriMed™ Patient Identification System as it was successfully utilized at the Hackensack University Medical Center. Emergency room medical staff had immediate, secure access to the patient’s identity and medical history after scanning his VeriChip microchip and linking it with the patient information file stored on the secure database. The patient was a Bergen County Police Officer who experienced head, neck and back injuries after a high speed chase that resulted in a car accident. This event represented the first time that a patient who had received a VeriChip was able to receive treatment from a hospital that also offered the system, highlighting the importance of the VeriChip system in critical situations. Lastly, InfoTech USA, Inc., a majority-owned subsidiary of Applied Digital entered into a partnership with SLPowers to deliver managed services solutions to its core market area in Northern New Jersey and Metropolitan New York City and beyond. Potential catalysts for the stock surrounding earnings could be news on the VeriChip IPO, solid results from that unit or strong results from Digital Angel. The stock ended the week at $1.53, down 5 cents.

Isonics Corporation (NASDAQ: ISON), a developer of innovative solutions for the homeland security and semiconductor markets, filed its annual report for its fiscal year ended April 30th showing 135% growth in sales to nearly $24 million. The company also made significant progress in all three of its operating divisions. The life sciences division has been stabilized with reduced operating costs and renegotiated contracts with suppliers and should begin to generate positive operating income in the near future. Similarly, the company’s semiconductor division has enjoyed steady growth after its entry into the 300mm silicon wafer market and currently has a robust order backlog which should lead to operating profitability for this division later this year according to management. Meanwhile, the security services division continues to exhibit strong growth and has accounted for $13 million in new revenues for ISON last year. Overall, it appears that such explosive growth, especially in the homeland security and semiconductor markets, should continue in the current fiscal year as well. Additionally, ISON has now regained compliance with Nasdaq Marketplace as a result of its Stockholders’ Equity being in excess of $2.5 million. The stock rose 9 cents for the week to close at $0.54.

Junior energy company Aspen Exploration Corporation (OTCBB: ASPN), is nearing completion of the first phase of operations in preparation to drill an underbalanced gas well in the West Grimes Gas Field, Colusa County, California. The WGU #15-12 well was conventionally drilled to a depth of 6,070 feet where the company will look to employ an underbalanced drilling technique in an attempt to find gas pay in the Forbes formation. Past results from this technique performed in this field have had excellent results where the company anticipates continued success. Aspen has a 5,000 plus acre lease position and a 21% operated working interest in this field. The stock ended the week at $5.00, up 50 cents.

Environmental business development company GreenShift Corporation (OTCBB: GSHF), announced that its majority-owned subsidiary GS CleanTech Corporation executed an agreement with ZeroPoint Clean Technology, Inc. for the exclusive rights to distribute and use ZeroPoint’s proprietary gasification, gas to liquids and fuel reforming technology in the Ethanol Production Industry. ZeroPoint’s Biomass Gasifier is designed to standardize variable biomass feeds and optimize high yields of high-quality syngas in real-time with greatly increased capital and operating cost efficiencies at smaller scales and adds significant additional capability to GS CleanTech’s clean fuel technology program.  Additionally, the company’s majority-owned subsidiary Hugo International Telecom, Inc. was renamed to GS AgriFuels Corporation with the trading symbol for the company’s common stock on the OTC Bulletin Board being changed to “GSGF.” Shares ended the week unchanged at $0.16.

Diversified sports media company HumWare Media Corporation (OTC: HMWM), was selected to operate the Ultimate Fantasy Football Contest with the Denver Broncos providing VIP prizes which include $20,000 in cash and early entries have a chance to win a new Ford Ranger. The Denver Broncos will be contributing a VIP Experience package of various prizes, including on-field pre-game passes to a Denver Broncos 2007 regular season home game for two, tickets in the exclusive United Club Level at Invesco Field, access to the post game press conference, VIP passes to the Broncos Barn before the game, scoreboard acknowledgement and PA announcement of contest winner on game day, and inside the ropes access to Broncos 2007 Training Camp at Dove Valley. Such selection of Humware by the Major League Marketing and the Denver Newspaper Agency speaks volumes about its service and reputation in the community and is a significant opportunity to increase exposure to the fantasy sports market for HumWare.  Additionally, the company has licensed JM Enterprises Group, Inc. as its sales representative for its Boondoggle Sports Network in the metropolitan New York City area. Shares ended the week unchanged at $0.11.

IMPART Media Group, Inc. (OTCBB: IMMG), an innovator in the creation of out-of-home digital advertising content and information network management, signed a non-exclusive distribution agreement with Visual Solutions Distributing, Inc. (VSDI) for the distribution of its revolutionary digital signage and interactive media platform called IQ Box(TM) through VSDI. Industry reaction following the May release of IQ Box has been very impressive since this product simplifies the deployment, management, and delivery of content to digital signage networks. Although terms of the distribution agreement were not disclosed, mutual expectations are for a minimum of 500 IQ Boxes to be sold by year-end 2007. Despite the news shares lost 19 cents last week to close at $0.81.

iVoice, Inc. (OTCBB: IVOI), a developer and licensor of proprietary technologies, reported that its subsidiary, iVoice Innovations, Inc., entered into an agreement to acquire four acres of land in Hanover County, Virginia, approximately 20 miles from Richmond, Virginia, together with all improvements, easements, water rights, mineral rights and other structures for a total cost of $800,000. The transaction is expected to close during the third quarter or fourth quarter 2006 where the company plans to use the location as the site of a proposed new biodiesel facility. A feasibility study is planned to start immediately where upon completion, engineering, design and permitting issues will be assessed in order to facilitate completion. Discussions are currently underway with potential partners, who could share in the development costs and provide additional expertise. Such news is significant for the company as this site is strategically located close to customers who could use its biodiesel. The stock ended last week unchanged at $0.07.

Volume Alert: Shares of Neutron Enterprises, Inc. (OTCBB: NTRN), a developer of digital media solutions, traded over 5 times average volume as investors showed enthusiasm regarding the appointment of Rory Olson as the new Chief Executive Officer late last month. Mr. Olson is a highly accomplished entrepreneur and public company executive with a proven track record of having founded, restructured and operated various companies from start-up stage to mature public company. Shares increased by 15 cents to close at $2.38 for the week.

Junior oil and gas producer, Patch International Inc. (OTCBB: PTCH), updated shareholders on its operating activities. Regarding its Rich/Rumsey, Alberta property, a test well was plugged back to a secondary formation after the primary target did not produce results. The company will review results and make a final analysis regarding the testing of this well or the drilling of a well at a new location. For its Halkirk, Alberta property, a test well was frac’d where the company is awaiting flow results from the operator. The seismic program for the Red Deer (Joffre), Alberta property has been completed and is currently being interpreted to determine the location of the first well which will commence drilling in mid-fall. Regarding the Atlee-Buffalo Area, Alberta property, Patch is awaiting advice from the operator as to the drill date of the well. The company is also awaiting advice from the operator as to the drill dates of wells located in the Lloydminster Area, Alberta property. The stock ended last week unchanged at $1.25.

Cell biology company Stem Cell Innovations (OTCBB: SCLL), commented on President Bush’s veto to further fund embryonic stem (ES) cell research last week stating that it supports expansion of the government’s role in stem cell biology and that its provides an alternative to ES cells with its patented, pluripotent stem cells. The company’s PluriCells™ are a type of pluripotent stem cell isolated from fetal tissue that has the ability to become all cell types of the body. Because they are developed from fetal germ cells, not viable embryos, they are eligible to be used in any NIH-funded laboratory. Management is excited about the opportunity presented by this product and has previously presented data demonstrating its ability to grow PluriCells™ efficiently and reproducibly without feeder layers. Shares ended the week at $0.25, down 11 cents.

USA Technologies, Inc. (OTCBB: USAT), a developer of cashless vending and energy management products, was issued another e-Port patent related to opening up the $44 billion vending market to cashless and Intelligent Vending. The company continues to expand its intellectual property which should greatly enhance shareholder value as major card companies are targeting vending as the next big cashless opportunity, making patents applicable to vending technology very critical. The latest e-Port patent, number 7,076,329 for Cashless Vending Transaction Management by a Vend Assist Mode of Operation, comes after USA Technologies signed an historic contract with MasterCard to deploy the first 1000 cashless vending machines equipped with the e-Port Generation Six transaction device. Additionally, the company announced that it filed a complaint against Transaction Network Services, Inc alleging that TNS has infringed its patent in connection with TNS’s cashless payment system for use with vending machines. The complaint requests that TNS be enjoined from further acts of infringement, an award of unspecified money damages against TNS, treble damages be assessed against TNS, and other relief. Shares were up 35 cents last week, closing at $7.85.

Universal Detection Technology (OTCBB: UDTT), a developer of early-warning monitoring technologies to protect people from bioterrorism and other infectious health threats, reported its listing on the Commercial Service’s list of Featured US Exporters (FUSE) in Israel. FUSE is a directory of US products featured on US Commercial Service websites around the world and gives US companies a valuable opportunity to target specific markets in the local language of business creating additional exposure to such companies. The stock closed at $0.02, unchanged for the week.

On the Wires: IMPART Media Group, Inc. (OTCBB: IMMG), an innovator in the creation of out-of-home digital advertising content and information network management, has hired industry veteran Stephen Wilson as its Vice President of Finance/ Corporate Controller where he will manage the financial planning and accounting practices of IMMG and help guide the company in its initiatives to rapidly expand in the out-of-home digital signage sector. Wilson brings 25 years of impressive experience and financial reporting acumen to the Impart team. Homeland security company. Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on oxidized glutathione for use in fighting cancer and hepatitis, announced that its company information has been made available via Standard & Poor’s Corporation Records Listing Program. Environmental business development company GreenShift Corporation (OTCBB: GSHF),  announced that its majority-owned subsidiary GS CleanTech Corporation was featured in an interview by PoultryCast on July 21st   which focused on GS CleanTech’s proprietary animal fat recycling technologies, including GS CleanTech’s dissolved air floatation sludge oil extraction system. PoultryCast is an audio program designed to meet the needs of today’s poultry professional and focuses on production practices, environmental stewardship, animal welfare and other relevant issues. Generex Biotechnology Corporation (NASDAQ: GNBT), a leader in the area of buccal drug delivery, continues its brand awareness campaign as it made two poster presentations of clinical data at the 33rd Annual Meeting & Exposition of the Controlled Release Society in Vienna, Austria last week. The data related to Generex Oral-lyn and Generex Metformin Gum. Such exposure is important as The Controlled Release Society represents an international organization which serves 3,000 members from more than 50 countries.

StockGuru Blog: Tasco Holdings to Operate Adipose Derived Stem Cell Bank (from liposuction)

Saturday, July 29th, 2006
Tasco Holdings International (OTCBB: THII) has been rated “Outperform” with a target price of $6.00 by Beacon Equity Senior Research Analyst, Kris Goldcross, CFA. The full report is available at http://www.BeaconEquityResearch.com

Tasco/Bio-Matrix may become the first company to operate an adipose-derived stem cell bank in the United States. Stem cells which are derived from fat tissues can easily, and ethically be harvested by elective liposuction, which is then stored in a frozen condition in liquid nitrogen at super-cooled temperatures. When needed, these stem cells can be thawed to potentially treat several diseases. The banking of cord blood is a once in a lifetime opportunity, which can only be done at the time of birth. However, by offering to preserve stem cells from adipose tissue, the company has significantly expanded its customer base.

Tasco/Bio-Matrix believes that though cord blood banking will help the company to generate earnings, the adipose tissue derived from stem cells will be its major source of earnings. Additionally, stem cell therapy commands the need for instrumentation, which is less invasive and friendly to both the target area as well as the tissue and cells. Tasco/Bio-Matrix has developed a full line of such disposable stem cell extraction surgical tools, which can be used to extract, transfer and re-introduce cells.

Given the growing number of liposuctions, demand for both the instruments as well as the company’s cryogenic storage facility is bound to increase. Given the immense opportunity in the stem cell research segment of the $75 billion growing biotechnology and medical device industry, the upcoming building in the heart of San Diego should help Tasco/Bio-Matrix generate significant earnings going forward.

About Tasco Holdings Inc.

Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

Source:

Beacon Equity Research – http://www.BeaconEquityResearch.com

Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.

Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.

Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517

StockGuru Blog: Tasco Holdings International Valuation by Beacon Equity Research

Saturday, July 29th, 2006
Tasco Holdings International (OTCBB: THII) has been rated “Outperform” with a target price of $6.00 by Beacon Equity Senior Research Analyst, Kris Goldcross, CFA. The full report is available at http://www.BeaconEquityResearch.com

Tasco/Bio-Matrix operates in a highly competitive industry characterized by several established local, regional and national companies with greater financial, management and marketing resources. For the last 15 years, commercial private cell banking (cord blood) has been available in the U.S.

Currently there are more than 23 cord blood banks operating in the U.S. with three companies (Cryo-Cell International, Inc.; Cord Blood Registry, and Viacell, Inc.) controlling 80% of the market share. In addition to the major players, there are several other smaller companies that are engaged in the same line of business as Tasco/Bio Matrix.

Many of these have already completed or implemented strategies that may enable them to establish a stronger position in this market. Additionally, the company believes that Mentor and Beckton Dickinson could provide competition to its medical line of disposable instruments. However, to date none of these companies have successfully either manufactured or distributed any disposable tissue management instruments. All three companies are primarily focused on reusable instrumentation for this industry.

However, reusable instruments run the risk associated with infectious disease transmission as well as damage to stem cells during the extraction process. On the other hand, Bio-Matrix’s disposable instrumentation results in higher cell yields and cell viability.

Valuation Model Used by Beacon Equity

Beacon Equity attempted to value the stock of the Tasco based on a price-to-sales model (P/S).

Since currently the company has significant exposure in the stem cell banking operations, Beacon Equity compared the market value of Tasco with other major operators in the industry including:

Cord Blood America (CBAI.OB); Regeneration Technologies (RTIX.OB) Geron Corporation (GERN), Viacell, Inc. (VIAC); Cryo-Cell International, Inc. (CCEL.OB); Thermogenisis Corp. (KOOL); StemCells, Inc. (STEM.OB); and Aastrom Biosciences, Inc. (ASTM).

Company Price per Share Market Cap In Millions Price Share Multiple
Cord Blood America 0.11 4.00 1.96
Regeneration Technololgies 6.00 179 2.37
Geron Corp. 6.15 405 65.83
Viacell, Inc. 4.04 156 3.51
Cryo-Cell International, Inc 2.22 26 1.79
Thermogenisis Corp. 3.94 216 21.24
Stem Cells, Inc. 2.31 180 871.65
Aastrom Biosciences 1.35 161 177.25

The average P/S multiple of the group stands at 16x (omi?ing StemCells, Inc. and Aastrom Biosciences, Inc. as they trade at exceptionally high multiples). Management expects to generate revenues of $5.03 million in the fiscal year 2007.

Applying a conservative P/S multiple of 15x on these estimates, the stock of Tasco Holdings (OTCBB: THII) would be fairly valued at $6.00 based on those number, which represents a significant appreciation possibility from current levels.About Tasco Holdings Inc. Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

Source:

Beacon Equity Research – http://www.BeaconEquityResearch.com

Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.

Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: Publisher@Stockguru.com.

Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517

StockGuru Blog: Tasco Holdings International Focuses on Adult Stem Cell Storage and Research

Friday, July 28th, 2006

Tasco Holdings International (OTCBB: THII) Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

Geoffrey Eiten, president of National Financial Communications, said, “With worldwide spending on medical research and technology growing at enormous rates — more than $14 billion in public and private funds is expected to be spent on stem cell research alone this year — agencies, such as those that offer stem cell research and related products, services and facilities stand to benefit over the near and long term. And their market positioning couldn’t be timelier to public funding debates.

“Having already invested substantial capital to construct and outfit a first-of-its-kind 15,000 square foot, FDA-compliant cGMP (Good Manufacturing Practices) and cGTP (Good Tissue Practices) facility for adult stem cell storage and research in the U.S., Tasco is uniquely positioned to capture its share of the estimated $75 billion a year biotech and medical device industry.”

Sources:

Beacon Equity Research – http://www.BeaconEquityResearch.com
Business Wire

Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517

About Tasco Holdings Inc.

Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.

Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.

Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

StockGuru Blog: Tasco Holdings International Rated ‘Outperform,’ Target $6.00 by Beacon Equity Research

Friday, July 28th, 2006
Tasco Holdings International (OTCBB: THII) has been rated “Outperform” with a target price of $6.00 by Beacon Equity Senior Research Analyst, Kris Goldcross, CFA. The full report is available at http://www.BeaconEquityResearch.com

In the report Mr. Goldcross writes, “The Company is engaged in the cryogenic storage of non-controversial stem cells and the development of medical devices used in live tissue transfer and stem cell research. Additionally, the Company has developed 192 disposable instruments for use in plastic surgery, tissue management and stem cell research. The company plans to commercialize these instruments to plastic surgeons and patients to efficiently help store stem cells.

“Since currently the company has significant exposure in the stem cell banking operations, we have compared the market value of Tasco with other major operators in the industry including Cord Blood America (OTCBB: CBAI); Viacell, Inc. (Nasdaq: VIAC); StemCells, Inc. (Nasdaq: STEM); Aastrom Biosciences, Inc. (Nasdaq: ASTM); Geron Corporation; Regeneration Technologies; Cryo-Cell International, Inc.; and Thermogenics, Corp.”

About Tasco Holdings Inc.

Tasco Holdings Inc. recently purchased Bio-Matrix Scientific Group Inc. (www.BMXGonline.com), a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market.

The Company aligns itself with strategic partners that offer key technologies in biomedical device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego, California, to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry.

Source:

Beacon Equity Research – http://www.BeaconEquityResearch.com

Safe Harbor Provision: This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements include “…will also allow us to expand the market for the Ginger Kelly Collection beyond North America, thereby greatly increasing shareholder value” and are based on the Company’s current expectations as to future events. However, the forward-looking events and circumstances discussed in this press release might not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. Risk factors include, lack of inventory financing, foreign currency fluctuations, availability of product, uncertainty concerning market acceptance of its products, competition and other risk factors as outlined in the Company’s SEC filings.

Forward Looking Statement: The information in this news release includes certain forward-looking statements that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements to the future financial performance of the Company. Although the Company believes that the expectations reflected in its forward- looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, successful performance of internal plans, product development and acceptance, the impact of competitive services and pricing, or general economic risks and uncertainties.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.

Disclosure: Pentony Enterprises LLC was compensated $10,000.00 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

Tasco Holdings International:
Bio-Matrix Scientific Group Inc
David Koos, 619-398-3517

StockGuru News: Mobile Ready Entertainment Corp. Announces B2B Travel and Entertainment Service; MyMobileConcierge Set to Launch in Fall

Friday, July 28th, 2006
Mobile Ready Entertainment Corp. Announces B2B Travel and Entertainment Service

Mobile Ready Entertainment Corporation (OTC:MBRN)

MyMobileConcierge Set to Launch in Fall

STROUDSBURG, PA–(MARKET WIRE)–Jul 28, 2006 — Mobile Ready Entertainment Corp. (Other OTC:MBRN.PK – News) and its wholly owned subsidiary Key2Travel announce its campaign to B2B mobile and wireless devices. MBRN will be launching a pioneering affinity marketing campaign specifically designed with small and medium business in mind called “MyMobileConcierge” that packages compelling entertainment content with great travel opportunities for consumers. The MyMobileConcierge service includes restaurant, nightlife, hotel, business service, museum listings and other localized information licensed from all award-winning premium content and information companies. Consumers will be able to access information for the 25 top U.S. cities and vacation destinations via their mobile phones or PDAs.

According to Erick Rodriguez, CEO of Key2Travel and SVP of Business Development for MBRN “With MyMobileConcierge, we’re offering comprehensive entertainment and travel information to consumers, while presenting great affinity opportunities on a unique mobile platform, complete with its hip, sleek branding.”

The platform is being developed for Mobile Ready by inside developers. A beta launch is expected in late 4th Quarter 2006.

“Like no other niche market, we see small to medium-sized business embracing the MyMobileConcierge service as a sophisticated way to extend travel and entertainment to employees and executives on the move,” said Josh Eikov, CEO of MBRN. “With more then 23M small and medium businesses we hope that at a price point of between $150-250 per year almost every small to medium-sized company in North America will start will reap the benefits of this new platform.”

About Mobile Ready Entertainment Corporation

Mobile Ready Entertainment Corporation is a wireless and media holding company specializing in the entertainment and educational vertical market segments. Through our subsidiaries we will develop, market and sell wireless application software and entertainment-based content for mobile devices. Our value proposition is to unlock, integrate and seamlessly deliver all types of data to wireless devices, whether streaming movies, music video or television content and digital radio delivery to the growing consumer market via channel and content partners — anytime, anywhere. We deliver these products and services globally across most of the major cellular networks and prominent wireless device operating systems. For more information about Mobile Ready, please visit its website at www.mymobilereadyec.com.

For information about Key2Travel please visit www.key2travel.com.

Forward-Looking Statement

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. The statements contained or incorporated by reference in this website that are not historical facts (including without limitation statements to the effect that Mobile Ready Entertainment Corp. (the “Company” or “Mobile Ready”) or its management “believes,” “expects,” “anticipates,” “plans,” “intends,” “foresees,” or other similar expressions) are forward-looking statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future developments and their potential effects on the Company.

There can be no assurance that future developments affecting the Company will be those anticipated by the Company. All comments concerning the Company’s expectations for future revenue and operating results are based on the Company’s forecasts for existing operations and do not include the potential impact of any future acquisitions. These forward-looking statements involve significant risks and uncertainties (some of which are beyond the Company’s control) and assumptions.

Contact:

Contact:
Mobile Ready Entertainment Corporation
Joshua Eikov
570-269-8303
josh@mymobilereadyec.com

Source: Mobile Ready Entertainment

View the StockGuru Profile for Mobile Ready Entertainment Corporation (OTC: MBRN):

http://www.stockguru.com/profiles/mbrn/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $15,000 by a non-controlling third party for profile coverage. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru Alert: Elgrande International, Inc (OTCBB: EGDI) Trading at Substantial Discount to Resistance Levels

Friday, July 28th, 2006
StockGuru Alert: Elgrande International, Inc (OTCBB: EGDI) Trading at Substantial Discount to Resistance Levels

Elgrande International, Inc. (OTCBB: EGDI)

Resistance Price (5day): $0.017 (A 29% Discount)

Resistance Price (20day): $0.025 (A 52% Discount)

Resistance Price (50day): $0.030 (A 60% Discount)

Source of data: Knobias.com

View the StockGuru Profile for Elgrande International (OTCBB: EGDI):

http://www.stockguru.com/profiles/egdi/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated 500,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

StockGuru First Look: Tasco Holdings International Inc. (OTCBB: THII)

Friday, July 28th, 2006
StockGuru First Look: Tasco Holdings International Inc. (OTCBB: THII)

Expect More on Our Newest Profile Tonight!

Tasco Holdings International Inc. (OTCBB: THII)

View the StockGuru Profile for Tasco Holdings International:

http://www.stockguru.com/profiles/thii/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $10,000 for profile coverage. Pentony Enterprises LLC is not a registered investment adviser or broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru News: Quintek (OTCBB: QTEK) Penetrates Healthcare Outsourcing Market with Focus on Risk Management Services

Friday, July 28th, 2006

Quintek Further Penetrates Healthcare Outsourcing Market with Focus on Risk Management Services

HUNTINGTON BEACH, Calif.–July 27, 2006–Quintek Technologies Inc. (OTCBB: QTEK), a global provider of Business Process Outsourcing (BPO) and best-of-breed technology consulting services, continues to expand into the large and fast-growing healthcare outsourcing market. Quintek estimates that the market for services it provides in this space to be $1.5 billion nationally. Quintek is now providing services for companies providing Risk Management services and seeking further growth in this market.

Robert Steele, Quintek CEO, added: “We estimate that the market for the services we provide in this space to be over $1.5 billion. In the healthcare arena we are currently providing ongoing services to the largest, independently owned healthcare practitioner, Credentials Verification Organization (CVO), in the world. Additionally, we have increased the services we provide to the largest biotechnology company in the world which represents a material increase in billings to this customer.” He continued, stating that, “Quintek has completed jobs directly or indirectly for Cedars Sinai Medical Center in Los Angeles, Long Beach Memorial Care, Alteer Corporation, Precyse Solutions as well as several multi-physician practices.” Steele ended, “Our focus on healthcare industry as well the other targeted industries will be the key to our continued success.”

David Lequeux, Quintek director of business development, stated: “I was brought on board to increase penetration into the large and lucrative healthcare industry. We are succeeding at that goal. We recently completed work for a physician-owned medical liability company, providing liability protection, rigorous underwriting, claims management priorities and very involved risk management programs for California physicians.” Lequeux added, “Additionally, together with our HIPAA-compliant partner Manhattan Data Inc. (MDI) we have been providing ongoing scanning services to VerifPoint for several months from which our revenue has doubled.” He ended, “We are stepping up our efforts in Healthcare and Risk Management services due to our recent customer successes and plan to continue to deliver the highest quality of services to the industry.”

About Quintek Technologies Inc.

Quintek Technologies Inc. (OTCBB:QTEK – News), through its wholly owned subsidiaries Quintek Services Inc. (QSI), and Sapphire Consulting Services Inc., provides services to enable Fortune 500 and Global 2000 corporations to reduce costs and maximize revenues.

QSI delivers Business Process Outsourcing (BPO) services and solutions that enable companies to secure and manage their key data processing demands with optimal efficiency and minimal costs. As a next-generation technology company, Quintek is unhindered by outdated information technology systems, and thus is able to deploy best-of-breed solutions in all aspects of BPO. The Aberdeen Group, a provider of IT market intelligence, forecasts 13 percent annual growth for the BPO industry through 2005, when the market is projected to reach $248 billion.

Sapphire Consulting Services Inc. offers a broad range of supply chain management consulting services. Sapphire assists organizations to create a higher level of customer satisfaction, enhance supply chain capability and achieve consistent competitive advantage through reduced product cost, reduced inventory investment and improved supply chain security. A study by IDC found the SCM services market will expand from $26.1 billion in 2002 to $40.5 billion in 2007, representing a five-year compound annual growth rate (CAGR) of 9.2 percent.

For more information, visit http://www.quintek.com.

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding potential sales, the success of the company’s business, as well as statements that include the word “believe” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Quintek to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in Quintek’s Annual Report on Form 10-KSB for the fiscal year ended June 30, 2005, and any subsequent reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and Quintek assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, inability to timely develop of products or services, inability to deliver products or services when ordered, inability of potential customers to pay for ordered products or services, and political and economic risks inherent in domestic and international trade.

Contact:

Quintek Technologies Inc.
Andrew Haag, 714-848-7741, ext. 14
ahaag@quintek.com

or

Cinapsys Inc.
Mark Moline (Communications), 760-458-4899
mark@cinapsys.com

For more information, visit:

http://www.quintek.com.

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Member area content is presented without compensation. Profiles, investment opinions, most interviews and trade alerts are issued for compensation. Details of compensation can be found below this statement for the companies shown above. Other details of compensation for all currently covered companies can be found on our web site, StockGuru.com.

We value your privacy, and offer an one click unsubscribe button above in the navigation bar of this email. We also honor all unsubscribe request by email. Send to: Publisher@StockGuru.com and we will honor your request. All unsubsribe requests are handled within 48 hours, and more often much sooner than that.

Disclosure: Pentony Enterprises LLC and our affiliates have been compensated $72,000 and 1.5 million shares of restricted 144 stock for profile coverage. Neither Pentony Enterprises LLC, nor our affiliates, are registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru News: Cavico Corporation (OTC: CVCP) Begins Auditing Process in Preparation for Application to List Its Shares on a Senior Exchange

Friday, July 28th, 2006
Cavico Corporation (OTC: CVCP)

Cavico Corporation Begins Auditing Process in Preparation for Application to List Its Shares on a Senior Exchange

LOS ANGELES, CA and HANOI, VIETNAM–(MARKET WIRE)–Jul 28, 2006 — Cavico Corporation (OTC: CVCP), a company working in the fields of infrastructure development, including the construction of hydropower facilities, dams, bridges, roads, mines and urban buildings throughout Vietnam and the Pacific Rim, has begun the process of auditing its financial statements. In a recent trip to Cavico Headquarters in Vietnam, a representative from Jaspers & Hall, PC, an auditing firm registered with the Public Company Accounting Oversight Board (PCAOB) to perform audits for fully-reporting publicly traded companies, met with Cavico’s executive officers to outline the steps necessary to complete a U.S. GAAP audit in preparation for listing the company’s shares on a senior exchange in the U.S.

“Cavico has begun the audit process and has laid out a timeline for completing the audits, in order to become fully-reporting with the Securities and Exchange Commission (SEC) and apply for listing on one of the major exchanges,” stated Timothy Pham, Assistant Secretary for Cavico Corporation. “I have met with representatives from both the NASDAQ and the NYSE to discuss the listing requirements of these exchanges. In both cases, I believe Cavico already meets the criteria for listing on either NYSE-ARCA or NASDAQ Global Market. However, first we must complete the audit process, which is an essential pre-requisite for listing.”

For more information about Cavico, please refer to the company’s website at: http://www.cavicocorp.com.

About Cavico Corporation

Cavico (www.cavicocorp.com), founded in 2000, is a major infrastructure construction, infrastructure investment, and natural resources conglomerate headquartered in Hanoi, Vietnam. The company is highly respected for its core competency in the construction of mission-critical infrastructure including hydroelectric plants, highways, bridges, tunnels, and urban community developments. One of the company’s primary competitive advantages is its ability to nurture a project “from concept through completion” with a vertical portfolio of interrelated investment, permitting, design, construction management, and facility maintenance services. Cavico’s project partners often include top multi-national corporations as well as government organizations. The company currently employs more than 3,000 people.

Vietnam’s transition to a market economy has generated rapid economic growth. The country’s impending ascension to the World Trade Organization is likely to provide an additional boost to economic growth and a further acceleration in the country’s current infrastructure construction boom. The aggressive development of Vietnam’s energy, transportation, and urban infrastructure is absolutely essential to the country’s ability to compete internationally, and this aggressive build-out is creating huge growth opportunities for infrastructure construction companies such as Cavico.

“Safe-Harbor” Statement

This press release contains forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding potential sales, the success of the company’s business, as well as statements that include the word “believe” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Cavico Corporation to differ materially from those implied or expressed by such forward-looking statements. Such factors include, among others, the risk factors included in reports filed with the SEC under the Exchange Act. This press release speaks as of the date first set forth above and Cavico Corporation assumes no responsibility to update the information included herein for events occurring after the date hereof. Actual results could differ materially from those anticipated due to factors such as the lack of capital, timely development of products and services, inability to deliver products and services when promised, inability of potential customers to pay for ordered products and services, and political and economic risks inherent in international trade.

Contact:

For Cavico Corporation:

Timothy Pham
Phone: 714-843-5456
Email: Email Contact

Cavico Corporation Investor Relations:

Cinapsys, Inc.
Mark Moline
Phone: 760-458-4899
Email: Email Contact

View the StockGuru Profile for Cavico Corporation:

http://www.stockguru.com/profiles/cvcp/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated 6,000 free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.

StockGuru Blog: Clearly Canadian Clears its Debt for Clear Sailing

Thursday, July 27th, 2006
CCBEFClearly Canadian Beverage Corp.Clearly Canadian Beverage Corp., the Vancouver-based speciality and flavoured waters group, has announced that it is effectively debt-free.

The company noted on July 26, 2006, that following recent financings and settlement of outstanding litigation, it was now, with the exception of regular trade payables, free of debt. Clearly Canadian added that it has increased its current cash position to more than US$5.3m.

“We now have a very strong financial foundation which could accelerate our efforts towards broadening distribution, increasing availability of our product lines, exploring all profitable alternatives related to our brand name and implementing our stated strategic initiatives,” said Clearly Canadian president Brent Lokash.

The litigation which the company has settled related to a 1997 claim surrounding its subsidiary Blue Mountain Springs. It involved, in part, a claim Clearly Canadian and Blue Mountain to repay an outstanding C$1.75m (US$1.54m) debt owed to Blue Mountain’s former owner.

Lokash added that the settlement allowed Clearly Canadian “to extinguish a significant debt for less than is being claimed against the company” and would enable the new management team “to focus on the positive aspects of developing new business and products”.

About Clearly Canadian

Based in Vancouver, B.C., Clearly Canadian Beverage Corporation markets premium alternative beverages and products, including Clearly Canadian® sparkling flavoured waters. Which are distributed in the United States, Canada and various other countries. Since its inception, the Clearly Canadian brand has sold over 90 million cases equating to over 2 billion bottles worldwide. www.clearly.ca.

Forward Looking Statements: Statements in this news release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes”, “estimates”, “potential”, “predicts”, “continue” and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analysis and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management, including, but not limited to, the Company’s or other’s belief that its new sparkling flavoured water line-up has an opportunity to succeed in the marketplace and open up new sales and distribution channels. These assumptions are subject to many risks, and actual results may differ materially from those currently anticipated. These risks include, by way of example and not in limitation, general economic conditions, changing beverage consumption trends of consumers, the Company’s ability to generate sufficient cash flows to support general operating activities and capital expansion plans, competition, pricing and availability of raw materials, the Company’s ability to maintain the current and future retail listings for its beverage products and to maintain favourable supply, production and distribution arrangements, laws and regulations and changes thereto that may affect the way the Company’s products are manufactured, distributed and sold and other factors beyond the reasonable control of the Company. Additional information on factors that may affect the business and financial results of the Company can be found in filings of the Company with the U.S. Securities and Exchange Commission and with the British Columbia and Ontario Securities Commissions.

Disclosure: Pentony Enterprises LLC expects to receive a total of $12,000 for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Contact:
Clearly Canadian Beverage Corporation
Shareholder Relations:
Steve Cook, 1-800-983-0993
investor@clearly.ca

Source:

Just-Drinks.com or http://just-drinks.com
Aroq Ltd. Seneca House, Buntsford Park Road, Bromsgrove, Worcs, B60 3DX, UK.

View the StockGuru Profile for Clearly Canadian Beverage Corporation: http://www.stockguru.com/profiles/ccbef/

StockGuru News: TAMG Cameroon Employees Begin Practical Training on New Equipment

Thursday, July 27th, 2006
TAMG Cameroon Employees Begin Practical Training on New Equipment

Transnational Automotive Group (OTCBB: TAMG)

SEATTLE, WASHINGTON–(MARKET WIRE)–Jul 27, 2006 — Transnational Automotive Group, Inc. (OTC BB:TAMG.OB – News), today announced that the Company’s first set of drivers and mechanics begin their familiarization and practical training on the new equipment that arrived at the port of Douala on 22 July.

40 of the first 80 drivers and 2 of the first 10 mechanics along with the training and support staff arrived in the city of Douala yesterday to begin the familiarization and practical training on the new buses. Once the buses clear customs, they will be driven 14 Km under escort to the Civil Military Engineer Base where the Minister of Defense and his regional commander Brigadier General Saly have kindly offered the logistics and training facilities at the Base.

“The facilities that we have been offered for very little cost include comfortable living and eating quarters, suitable class room facilities as well as the use of the road network on the base where we can safely drive the buses during this initial familiarization phase of the training”, said Chris Robertson, the Program Manger for TAMG-Cameroon. “Our training program includes basic familiarization on the new buses as well as convoy driving discipline. The rest of the training will be completed when the buses arrive at their eventual destination at the city bus depot in capital city of Yaounde.”

The buses are scheduled to convoy under escort from Douala to Yaounde – a 250KM highway trip – once the initial training has been completed. Once the buses arrive in Yaounde, the rest of the 80 drivers and 10 mechanics will complete their training. The Company has also planned a number of weeks of operational testing before commissioning the buses for operation. The launch of the first two city bus lines in Yaounde is scheduled for early September.

“This familiarization and practical training follows a number of weeks of teaching and driver theory training where we were able to select the best drivers Cameroon has to offer”, concluded Mr. Robertson.

Transnational Automotive Group (OTC BB:TAMG.OB – News), a Nevada corporation, is a transportation management, sales and manufacturing company. Our vision is to become a leading provider of transportation management and vehicle sales in the developing world. Headquartered in Seattle, WA, TAMG has been established through key acquisitions of leading transportation and automotive businesses.

This news release contains certain “Forward-Looking Statement” within the meaning of Section 21E of the United States Security Exchange Act of 1934. All statements, other than of historical fact, included herein are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations are disclosed in the Company’s documents files from time to time with the Securities Exchange Commission.

Contact:

Transnational Automotive Group, Inc.
Mr. Terry Klapakis
President
(206) 262-7415
(206) 262-7813 (FAX)
tklapakis@transauto-group.com

http://www.transauto-group.com

Source: Transnational Automotive Group, Inc.

View the StockGuru Profile for Transnational Automotive Group:

http://www.stockguru.com/profiles/tamg/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated $46,000 by a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru Blog: THE IMMUNE RESPONSE CORPORATION PRESIDENT, Joseph F. O’Neill, MD, Discusses Valuation of IMNR

Thursday, July 27th, 2006

IMNR – The Immune Response Corporation Stock Guru found the new President of The Immune Response Corporation, Dr. Joseph F. O’Neill, on the road today, mid-way during his speaking tour. He took time between speaking engagements to share his opinion on IMNR’s value potential.

Dr. O’Neill believes the new direction of IMNR is creating investor value by focusing equally on MS and HIV/AIDS. He also stressed that the IMNR’s multiple sclerosis (MS) program may provide a platform in potentially new applications for autoimmune diseases including psoriasis and rheumatoid arthritis (RA).

“We have implemented a new clinical development strategy. We are going forward with our HIV/AIDS second generation vaccine which is based on Remune® but includes a Toll-like receptor (TLR) agonist and it is more potent. Additionally, we are investing in development of our MS vaccine.”

“Our value message is that we provide a rare opportunity for return on investment in that we have two Phase 2 products, each with the potential to become a multibillion dollar drug. In addition we believe we have great potential for advances in rheumatoid arthritis and psoriasis.”

Referring to the recent removal of rheumatoid arthritis (RA) drugs from the market Dr. O’Neill addressed the importance of providing new therapies in that area. “There is a tremendous medical vacuum in the field of rheumatoid arthritis and we will be in a position to make advances in these areas as well. After all, we are an established company building on twenty years of research.”

� Dr. O’Neill felt this was the most important element of his value message: “No where can you find a biotech company with twenty years of research experience under its belt with two Phase 2 products, each with multibillion dollar potential.”

Dr. O’Neill has a sincerity in his voice when he speaks. “We have the proven experience to navigate successfully in the regulatory environment. I think it’s clear that we know what we are doing and we are on an important path here. I want the scientific community and the investment community to understand the significance of what we’re doing. They don’t always have the time to come to us, that’s why I’m going to them.”

“I think the Incremental Advantage Report does a good job of sharing the value message of our company.”

Dr. O’Neill is committed to going anywhere and everywhere he can to deliver the message of The Immune Response Corporation.

To Access IncreMental Advantage Research Report CLICK HERE: http://www.pinksheets.com/quote/company_profile.jsp?symbol=IMNR.For additional information, please email ROI Group Associates at imnr@roiny.com or call Mike Dodge at 212-495-0744.

The Immune Response Corporation is focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in phase 2 clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.

NeuroVax™, which is based on the Company’s patented T-cell receptor ( TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn disease.

IR103 is based on the Company’s patented whole-inactivated virus technology, co-invented by Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of Remune®, the Company’s first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to generate enhanced HIV-specific immune responses. The Company is currently testing IR103 in two phase 2 clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.

ABOUT THE IMMUNE RESPONSE CORPORATION The Immune Response Corporation (OTCBB: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. Their lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of multiple sclerosis (MS) and IR103 for the treatment of Human Immunodeficiency Virus (HIV). Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. NeuroVax™, which is based IMNR’s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong disease specific cell mediated immunity in nearly all patients treated by enhancing levels of FOXP3+ T Regulatory (Treg) cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease. In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.

Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.Disclosure: Pentony Enterprises LLC was compensated $17,500 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
� Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: Publisher@Stockguru.com.

Source: ROI Group Associates – Contact for more information
39 Broadway; NY, NY 10006
212.495.0744
mdodge@roiny.com
IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080�

StockGuru News: Bolivia’s Minister of Mines and Metallurgy Announces Guarantee of Operations & Support for FMNJ & COMIBOL Mining Efforts

Thursday, July 27th, 2006
Bolivia’s Minister of Mines and Metallurgy Announces Guarantee of Operations & Support for FMNJ & COMIBOL Mining Efforts

Franklin Mining (OTC: FMNJ)

LAS VEGAS, NV–(MARKET WIRE)–Jul 27, 2006 — Franklin Mining, Inc. (Other OTC:FMNJ.PK – News) CEO Jaime Melgarejo announced today that Bolivia’s Minister of Mines and Metallurgy, Walter Villarroel Morochi, released a written statement of support and commitment to organize and “guarantee a normal functioning mining operation” for COMIBOL and FMNJ. Bolivia’s Minister was also quoted from a press conference, promoting mining development with the assurance that “Bolivia remains competitive on an international level.”

In addition to the letter of commitment addressed to Franklin Mining, the press conference was held on May 3, 2006, with the Prospectors and Developers Association of Canada Convention in Toronto. Bolivian Minister of Mines and Metallurgy, Mr. Walter Villarroel Morochi, addressed the need to “create a competitive and secure environment for mining investment that will foster job creation, infrastructure modernization and industry partnership.”

Morochi was quoted as saying, “We believe that many of these existing mining areas and areas with new potential, when properly evaluated with modern exploration technology and mining techniques, will highlight the potential for the discovery of important mineral deposits — deposits which can surely have the opportunity to be transformed into business enterprises of world-wide importance.”

“One of the key objectives of my office is to send a positive message to participants at the annual convention of the PDAC, to attract investor interest in developing and expanding the small existing mining operations, as we are confident that there are very high probabilities of finding many more important mineral deposits. Currently, we have an extensive list of investment requests from mining cooperatives and active mining companies that range from one-half million dollars to 2 million dollars. These are important opportunities that are available to be taken advantage of.”

“Furthermore, we will take measures that will encourage investment in ventures both large and small. One example of this will be the declaration of ‘integrated mining areas’ that will respect pre-existing mineral rights in areas where many small mining concessions exist by unifying development efforts. This will allow the Bolivian state to promote the search of strategic partners for the development of these areas. ”

“This is just one example of several measures that will be taken to promote mining development and ensure Bolivia remains competitive on an international level. We are pleased and very willing to provide any information that the investors interested in our country will require. ”

“I am pleased to have this opportunity to send the message from the President, that we are working hard to establish the legal security that investment in the mining industry requires on a long term basis.”

To read more details on the support of the Bolivian government and the Minister of Mines and Metallurgy, please visit http://www.mineria.gov.bo/.

Franklin Mining, Bolivia S.A. (a Bolivian corporation) is a subsidiary company of Franklin Mining, Inc. COMIBOL is Bolivia’s state-owned mining company.

For additional information on Franklin Mining, Inc, please visit our web-site, www.franklinmining.com. To receive Franklin Mining news by e-mail, please send contact information to info@franklinmining.com.

DISCLOSURES:

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that are subject to risk and uncertainties, including, but not limited to, the impact of competitive products, product demand, market acceptance risks, fluctuations in operating results, political risk and other risks detailed from time to time in Franklin Mining, Inc.’s filings with the Securities and Exchange Commission. These risks could cause Franklin Mining Inc.’s actual results to differ materially from those expressed in any forward-looking statements made by, or on behalf of, Franklin Mining Inc.

Additional information on company operations is found at our website http://www.franklinmining.com/.

Contact:

Contact:
Franklin Mining, Inc.
Andrew Austin
702-386-5379
info@franklinmining.com

Source: Franklin Mining, Inc.

View the StockGuru Profile for Franklin Mining:

http://www.stockguru.com/profiles/fmnj/

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. Disclosure: Pentony Enterprises LLC was compensated four million free trading shares from a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. It is the policy of Pentony Enterprises LLC to sell all shares of this and any company featured. Anyone considering any company we feature in consideration for free trading shares should consider this.� We currently hold 265,000 shares of Franklin Mining.

StockGuru News: Oxford Media and QuadTech International

Thursday, July 27th, 2006
Oxford Media, Inc. (OTCBB: OXMI)

The Grandview Hotel in Kansas City, Missouri Selects Oxford Media’s Video-on-Demand Services

IRVINE, Calif., July 27 /PRNewswire-FirstCall/ — Oxford Media, Inc. (OTC Bulletin Board: OXMI – News), a leading developer of scalable, turnkey hybrid digital VOD and PPV entertainment systems, announced today it has signed an agreement with the Grandview Hotel in Kansas City, Missouri, through one of its Platinum Dealers, Broadband Data Communications, Inc. for digital Video-on-Demand and Pay-Per-View entertainment to its 144 rooms. Installation is scheduled to be completed in September 2006.

Read full release here:

http://stockguru.com/profiles/oxmi/news.php

QuadTech International, Inc. (OTCBB: QTII)

QuadTech International Clarifies Inaccuracies on Yahoo Finance Profile

VANCOUVER, BC–(MARKET WIRE)–Jul 27, 2006 — QuadTech International, Inc. (”QuadTech”) (OTC BB:QTII.OB – News), a global provider of leading-edge Internet and IP-based technology solutions for selected enterprises including the mining industry, today clarified numerous inaccuracies found in the Company’s profile on Yahoo Finance and other financial portals.

Read full release here:

http://stockguru.com/profiles/qtii/news.php

We Invite you to Visit the All New StockGuru Blog!

Here you will find updates on all our covered companies, including Profiled Companies and StockGuru Picks.

Click HERE to visit the Blog, or go to:

http://stockguru.com/blog/

StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 458-4258. Web: StockGuru.com. Email: Publisher@stockguru.com. OXMI Disclosure: Pentony Enterprises LLC was compensated 21,500 restricted 144 shares for profile coverage (from Pasadena Capital Partners). Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. QTII Disclosure: Pentony Enterprises LLC was compensated $46,000 by a non-controlling third party for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

StockGuru Blog: Interview with the New CEO of The Immune Response Corporation

Wednesday, July 26th, 2006
IMNRThe Immune Response Corporation

Stock Guru caught the new President of The Immune Response Corporation, Dr. Joseph F. O’Neill, today mid-way during his speaking tour promoting the new and exciting direction of IMNR.


“Our message is that we are building on twenty years of research with a dynamic new direction. We are building on an old company while becoming a new company. I left the White House to head up this company because I strongly believe in what we are doing and what we can do.” Dr. O’Neill thinks his message is important in the world of AIDS research. “Our approach is unique. No one else is currently working with this approach.”

Dr. O’Neill is an ‘insider’ in research and policy and has a unique role to play in this campaign of knowledge. He is working to get IMNR’s story out. He and his assistants have covered New York, Boston, Montreal, Vancouver, Florida, The Rodman and Renman Conference in Monaco and participated in several webcasts. IMNR will be attending a Toronto Conference August 13-18, 2006, as well. “I believe we are the only company out there with two Phase 2 products � in a field with the potential to become a multibillion dollar company.”

“I want the focus of the scientific community as well as the investment community. We recently made a presentation on the floor of the American Academy of Neurology� regarding our NeuroVax product. We also presented at the International AIDS Society in Toronto. Those are the very visible aspects of our presentations but I am also meeting behind the scenes with the leaders of research universities where I am sharing our findings and with that information exchange generating an interest in our work. This is important because these are the major medical centers. This is where the opinion leaders in and the intellectual leadership of our fields of research are found. Their support helps IMNR in terms of bettering study designs, forming alliances, and toning up research. These resources will serve us for many, many years.”

IMNR is an immuno-pharmaceutical Company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of MS and IR103 for the treatment of HIV/AIDS infection.More to come on the impact of this speaking tour on the value of the company, IMNR.
To Access IncreMental Advantage research report CLICK HERE: http://www.roiny.com/clients-irc-research.php.

For additional information, please email ROI Group Associates at imnr@roiny.com or call Mike Dodge at 212-495-0744.


Any information regarding The Immune Response Corporation (”IMNR”) in this communication is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. ROI Group Associates, Inc. (”ROI”) is the investor relations counsel for IMNR and accepts compensation from the IMNR for this effort, including a monthly cash retainer and restricted stock. Under the terms of its investor relations Service Agreement, ROI has agreed not to sell any of the IMNR restricted stock received as compensation under the Service Agreement during the entire term of its engagement as IMNR’s investor relations counsel pursuant to this Service Agreement. ROI shall be under no obligation to update readers about any restrictions on its trading activities regarding IMNR.� � � �
ABOUT THE IMMUNE RESPONSE CORPORATION The Immune Response Corporation (OTCBB: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. Their lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of multiple sclerosis (MS) and IR103 for the treatment of Human Immunodeficiency Virus (HIV). Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. NeuroVax™, which is based IMNR’s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong disease specific cell mediated immunity in nearly all patients treated by enhancing levels of FOXP3+ T Regulatory (Treg) cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease.
In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.

Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.

Disclosure: Pentony Enterprises LLC was compensated $17,500 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.

For further information contact:
ROI Group Associates
39 Broadway; NY, NY 10006
212.495.0744

MDodge@roiny.com

Source:

IMNRImmune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080

StockGuru Blog: IncreMental Advantage Research Report Indicates Immune Response Could Become Quite Profitable Even With Low Market Penetration Rates

Wednesday, July 26th, 2006

IMNR – The Immune Response Corporation

IncreMental Advantage, an equity research firm, has initiated coverage of The Immune Response Corporation (OTCBB: IMNR) with an accumulate rating.

IncreMental Advantage IMNR Research Report

IncreMental Advantage’s research report on The Immune Response Corporation is available at http://www.roiny.com/clients-irc-research.php . This report indicates that Immune Response could become quite profitable even with low market penetration rates.

Revenues and Earnings Estimates

The markets for the Immune Response Corporation’s products are so large that a successful product would bring significant revenues with only a small market penetration.

The Incremental Advantage Report indicates: “Based on our projections of expenses and cash inflow, we estimate the Company has enough cash on hand-this assumes exercise of all investor warrants, at the very least-to fund all of their programs through the end of 2007. These estimates exclude funding from grants and sponsorship of the trials.”

Income Potential

“The markets for autoimmune diseases and HIV/AIDS are both quite large and could bring substantial revenues if the products are successful. The multiple sclerosis indication currently has a population of about 425,000 patients in the U.S. and about 450,000 patients in Europe. As mentioned earlier in this report, the current therapies leave substantial room for improvement and roughly half of the patients are not on any therapy. Even if the multiple sclerosis therapy were priced at the low end of the pricing range for MS therapies that typically cost $12,000 to $20,000 per year, the Company could generate revenues in the hundred of millions with just a small market share.”

Stay tuned – Tomorrow the new CEO of IMNR addresses the issue of valuation in interview with Stock Guru.

To Access IncreMental Advantage Research Report CLICK HERE: http://www.roiny.com/clients-irc-research.php.

For additional information, please email ROI Group Associates at imnr@roiny.com or call Mike Dodge at 212-495-0744.


� �

Any information regarding The Immune Response Corporation (”IMNR”) in this communication is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein. THE READER SHOULD VERIFY ALL CLAIMS AND DO ITS OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. ROI Group Associates, Inc. (”ROI”) is the investor relations counsel for IMNR and accepts compensation from the IMNR for this effort, including a monthly cash retainer and restricted stock. Under the terms of its investor relations Service Agreement, ROI has agreed not to sell any of the IMNR restricted stock received as compensation under the Service Agreement during the entire term of its engagement as IMNR’s investor relations counsel pursuant to this Service Agreement. ROI shall be under no obligation to update readers about any restrictions on its trading activities regarding IMNR.

ABOUT THE IMMUNE RESPONSE CORPORATION The Immune Response Corporation (OTCBB: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. Their lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of multiple sclerosis (MS) and IR103 for the treatment of Human Immunodeficiency Virus (HIV). Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression. NeuroVax™, which is based IMNR’s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong disease specific cell mediated immunity in nearly all patients treated by enhancing levels of FOXP3+ T Regulatory (Treg) cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease.

In addition to MS, IMNR has opened Investigational New Drug Applications (IND) with the U.S. Food and Drug Administration (FDA) for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis. IR103 is based on their patented whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE® , our first-generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. IMNR is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naïve HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines. In early 2006 IMNR made a strategic decision to accelerate the development of IR103, rather than pursue a Phase III trial with REMUNE® . All of IMNR products are still in the development stage. IMNR has never had revenues from the sale of products. IMNR was founded in 1986.

Forward Looking Statement: This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. While these statements are meant to convey to the public the company’s progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management’s opinion. While management believes such representation to be true and accurate based on the information available to the company, actual results may differ materially from those described. The company’s operations and business prospects are always subject to risks and uncertainties. Important facts that may cause actual results to differ are set forth in IMNR’s periodic filings with the U.S. Securities and Exchange Commission.

Disclosure: Pentony Enterprises LLC was compensated $17,500 from ROI Group Associates Inc. for profile coverage. Pentony Enterprises LLC is not a registered investment advisers or broker/dealers. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

Disclosure: StockGuru.com is owned and operated by Pentony Enterprises LLC, 9555 Lebanon Road, Suite 103, Frisco, Texas 75035. Telephone: (214) 453-4258. Web: StockGuru.com. Email: http://www.stockguru.com/blog/Publisher@Stockguru.com.

For further information contact:
ROI Group Associates
39 Broadway; NY, NY 10006
212.495.0744
mdodge@roiny.com

Source:

IMNR — Immune Response Corp. (The)
5931 Darwin Court
Carlsbad, CA 92008
Website: http://www.imnr.com
Phone: 760-431-7080